pharmaceutical product
AstraZeneca’s Profit Gains on Sales of Cancer Drugs: AstraZeneca Plc’s profit rose in the first quarter, buoyed by demand for its cancer blockbusters Imfinzi and ...
bloomberg.com/news/articles/2024-04-25/astrazeneca-s-profit-gains-on-sales-of-cancer-drugs
AstraZeneca Drug Slows Progression in Advanced Lung Cancer: AstraZeneca Plc shares rose after trial data showed Tagrisso slowed disease progression in patients ...
trib.al/oOwrPah
Mixed Outcomes in European Markets; U.S. Approval Elevates AstraZeneca: On February 19, European stock markets displayed mixed outcomes, halting a three-day gain ...
riotimesonline.com/mixed-outcomes-in-european-markets-u-s-approval-elevates-astrazeneca/
In today’s (very) brief headlines... House sales surge, and can an AstraZeneca drug slow disease progression? 🩻
1. Buyer interest is on the rise once more ... Show more www.cityam.com/house-sales-surge-as-green-shoots-emerge-in-property-market/ www.cityam.com/astrazeneca-tagrisso-drug-shows-highly-impactful-results-in-lung-cancer-trial/ www.cityam.com/inside-bafta-2024-how-awards-ceremony-takes-over-london/ #houseprices #housesales #housingcrisis #astrazeneca #lungcancer #cancertrial #cancerdrug #baftas #openheimer #christophernolan #cillianmurphy #entertainmnetnews #businessnews #economy #cityamnews
AstraZeneca's Tagrisso-chemo combo given priority review in US: A combination of AstraZeneca's (AZN.L) blockbuster cancer drug Tagrisso, with chemotherapy to ...
reuters.com/business/healthcare-pharmaceuticals/astrazenecas-tagrisso-chemo-combo-given-priority-review-us-2023-10-16/
J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug: Johnson & Johnson (JNJ.N) said on Thursday its cancer drug combination helped ...
reuters.com/business/healthcare-pharmaceuticals/jjs-lung-cancer-therapy-combo-succeeds-late-stage-study-2023-09-28/
AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer drug-analysts
reuters.com/business/healthcare-pharmaceuticals/astrazenecas-tagrisso-chemo-combo-results-raise-bar-jj-cancer-drug-analysts-2023-09-11/
Quick Glance: AstraZeneca's Tagrisso-Chemo Combo Sets New Standard for J&J Cancer Drug - Analysts
- Combining AstraZeneca's blockbuster cancer drug Tagrisso with chemotherapy in a late-stage trial raises the bar for Johnson & Johnson's rival treatment.
- The FLAURA2 trial shows that adding chemotherapy to Tagrisso reduces the risk of disease progression or death by 38% compared to Tagrisso alone.
- The median progression-free survival is 29.4 months, a 9.5 month improvement over patients given only Tagrisso.
- Analysts see Tagrisso as an important driver of growth and consider these data as risk-reducing for AstraZeneca.
J&J says drug combo contains lung cancer from spreading for longer duration: Johnson & Johnson (JNJ.N) said on Wednesday its combination drug helped increase the ...
reuters.com/business/healthcare-pharmaceuticals/jj-says-drug-combo-contains-lung-cancer-spreading-longer-duration-2023-09-06/
Quick Glance: J&J drug combo extends duration of lung cancer progression
- Combination of Rybrevant and Lazertinib increases progression-free duration in NSCLC patients.
- Study shows positive results in patients with EGFR mutation.
- Johnson & Johnson expects therapy to become first-line treatment.
AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients
reuters.com/business/healthcare-pharmaceuticals/astrazenecas-tagrisso-slashes-death-risk-certain-post-surgery-lung-cancer-2023-06-04/
Lung Cancer: New Hope in Pill Form: Lung cancer is common - and especially deadly. A study now shows that pills taken after surgery cut mortality in half ...
zeit.de/gesundheit/zeit-doctor/2023-06/lungenkrebs-tabletten-tagrisso-medikament-studie
Paid articlePaid
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics